JP2018002724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018002724A5 JP2018002724A5 JP2017165302A JP2017165302A JP2018002724A5 JP 2018002724 A5 JP2018002724 A5 JP 2018002724A5 JP 2017165302 A JP2017165302 A JP 2017165302A JP 2017165302 A JP2017165302 A JP 2017165302A JP 2018002724 A5 JP2018002724 A5 JP 2018002724A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence represented
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2012/002211 | 2012-05-23 | ||
| PCT/EP2012/002211 WO2013174404A1 (en) | 2012-05-23 | 2012-05-23 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513043A Division JP6203830B2 (ja) | 2012-05-23 | 2013-05-21 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019034057A Division JP6833885B2 (ja) | 2012-05-23 | 2019-02-27 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018002724A JP2018002724A (ja) | 2018-01-11 |
| JP2018002724A5 true JP2018002724A5 (https=) | 2018-02-22 |
| JP6490763B2 JP6490763B2 (ja) | 2019-03-27 |
Family
ID=48651960
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513043A Active JP6203830B2 (ja) | 2012-05-23 | 2013-05-21 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2017165302A Active JP6490763B2 (ja) | 2012-05-23 | 2017-08-30 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2019034057A Active JP6833885B2 (ja) | 2012-05-23 | 2019-02-27 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2021015688A Active JP7204791B2 (ja) | 2012-05-23 | 2021-02-03 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2022212169A Pending JP2023038230A (ja) | 2012-05-23 | 2022-12-28 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2025023576A Pending JP2025093926A (ja) | 2012-05-23 | 2025-02-17 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513043A Active JP6203830B2 (ja) | 2012-05-23 | 2013-05-21 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019034057A Active JP6833885B2 (ja) | 2012-05-23 | 2019-02-27 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2021015688A Active JP7204791B2 (ja) | 2012-05-23 | 2021-02-03 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2022212169A Pending JP2023038230A (ja) | 2012-05-23 | 2022-12-28 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2025023576A Pending JP2025093926A (ja) | 2012-05-23 | 2025-02-17 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US9433675B2 (https=) |
| JP (6) | JP6203830B2 (https=) |
| KR (4) | KR102514338B1 (https=) |
| CN (3) | CN104427999B (https=) |
| AR (1) | AR091131A1 (https=) |
| AU (4) | AU2013265637B8 (https=) |
| BR (1) | BR112014028941B8 (https=) |
| ES (2) | ES2784855T3 (https=) |
| HK (1) | HK1208151A1 (https=) |
| HR (1) | HRP20220897T8 (https=) |
| HU (1) | HUE059241T2 (https=) |
| IL (3) | IL276434B2 (https=) |
| LT (1) | LT3725810T (https=) |
| MX (5) | MX367241B (https=) |
| NZ (1) | NZ701575A (https=) |
| PL (1) | PL3725810T3 (https=) |
| PT (1) | PT3725810T (https=) |
| RS (1) | RS63437B1 (https=) |
| RU (1) | RU2662066C2 (https=) |
| SG (2) | SG10201609510UA (https=) |
| SI (1) | SI3725810T1 (https=) |
| SM (1) | SMT202200325T1 (https=) |
| UA (1) | UA115985C2 (https=) |
| WO (2) | WO2013174404A1 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| DK3725810T3 (da) | 2012-05-23 | 2022-07-25 | Astellas Pharma Inc | Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer |
| WO2014075788A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN107531787B (zh) | 2015-01-27 | 2022-01-18 | 拉法医疗有限公司 | 靶向cd1d的单域抗体 |
| WO2016165765A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| JP6890831B2 (ja) | 2015-07-08 | 2021-06-18 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖ予備免疫化および免疫療法 |
| EP4295914A3 (en) | 2015-09-03 | 2024-04-10 | The UAB Research Foundation | Genetically-engineered drug resistant t cells and methods of using the same |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| DK3402483T3 (da) | 2016-01-15 | 2024-01-02 | American Gene Tech Int Inc | Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler |
| US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| DK3426777T3 (da) | 2016-03-09 | 2022-04-25 | American Gene Tech Int Inc | Kombinationsvektorer og fremgangsmåder til behandling af cancer |
| US11976292B2 (en) | 2016-06-08 | 2024-05-07 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| IL284348B2 (en) | 2016-07-08 | 2025-06-01 | American Gene Tech Int Inc | Hiv pre-immunization and immunotherapy |
| JP7176756B2 (ja) | 2016-07-21 | 2022-11-22 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | パーキンソン病を処置するためのウイルスベクター |
| CA3057142A1 (en) | 2017-04-03 | 2018-10-11 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| CA3064442A1 (en) | 2017-06-16 | 2018-12-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| CN107177549A (zh) * | 2017-06-29 | 2017-09-19 | 青岛麦迪赛斯医疗技术有限公司 | 一种简单高效的扩增γδT细胞的方法 |
| JP7381083B2 (ja) * | 2017-09-08 | 2023-11-15 | フォスプラティン テラピューティクス インコーポレイテッド | 免疫調節剤としてのホスファプラチン化合物およびその治療的使用 |
| JP7398380B2 (ja) * | 2018-03-08 | 2023-12-14 | フェインズ セラピューティクス，インコーポレーテッド | 抗クローディン１８．２抗体及びその使用 |
| US11485782B2 (en) * | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| SG11202007074PA (en) | 2018-05-18 | 2020-08-28 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
| US11505618B2 (en) * | 2018-07-18 | 2022-11-22 | Askgene Pharma Inc. | Antibodies and methods for making and using the same |
| EP3878863A4 (en) * | 2018-08-27 | 2022-06-22 | Nanjing Sanhome Pharmaceutical Co., Ltd. | ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE |
| WO2020060406A1 (en) | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
| US20220033491A1 (en) * | 2018-09-30 | 2022-02-03 | Cafa Therapeutics Limited | Combination therapy of cldn18 antibody and chemotherapy drugs |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| JP7458399B2 (ja) * | 2018-12-07 | 2024-03-29 | ゼットリップ ホールディング リミテッド | 抗クローディン抗体及びそれらの使用 |
| CN113227146B (zh) * | 2018-12-28 | 2024-03-01 | 南京金斯瑞生物科技有限公司 | 密蛋白18.2结合部分和其用途 |
| US12297265B2 (en) | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| CN113227135B (zh) * | 2018-12-28 | 2025-03-21 | 斯帕克斯治疗公司 | 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法 |
| CN114106183B (zh) * | 2019-01-15 | 2023-06-23 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| US20220184126A1 (en) * | 2019-03-29 | 2022-06-16 | Phanes Therapeutis, Inc. | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
| CN117659190A (zh) * | 2019-05-16 | 2024-03-08 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
| WO2020228806A1 (zh) * | 2019-05-16 | 2020-11-19 | 齐鲁制药有限公司 | 针对密蛋白18a2的抗体及其应用 |
| WO2020238730A1 (zh) * | 2019-05-24 | 2020-12-03 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| EP3929214A4 (en) * | 2019-05-30 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CLAUDIN 18.2 |
| WO2021024020A1 (en) * | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| PE20211147A1 (es) | 2019-08-12 | 2021-06-28 | I Mab Biopharma Us Ltd | Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso |
| EP4039702A1 (en) * | 2019-09-16 | 2022-08-10 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-b7-h3 antibody and application thereof |
| CN112574307B (zh) * | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
| CN112707965A (zh) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | 靶向cldn18.2的抗体及其制备方法和应用 |
| EP4069738A1 (en) | 2019-12-06 | 2022-10-12 | SOTIO Biotech a.s. | Humanized cldn18.2 antibodies |
| CN114761433B (zh) * | 2019-12-11 | 2025-07-29 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
| WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| CN114901365B (zh) | 2019-12-23 | 2025-07-15 | 斯迪安生物技术公司 | 肿瘤特异性密蛋白18.2抗体 |
| IL298184A (en) * | 2020-05-15 | 2023-01-01 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Antibody drug conjugate, preparation method therefor and use thereof |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| CN111705085B (zh) * | 2020-08-20 | 2020-12-25 | 北京百奥赛图基因生物技术有限公司 | 构建动物模型的方法及应用 |
| EP4214233A1 (en) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| JP2022061640A (ja) * | 2020-10-07 | 2022-04-19 | 株式会社村田製作所 | 積層セラミックコンデンサ |
| WO2022100590A1 (zh) * | 2020-11-10 | 2022-05-19 | 齐鲁制药有限公司 | 针对密蛋白18a2的adcc增强型人源化抗体及其应用 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| CA3199830A1 (en) | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
| WO2023066267A1 (en) * | 2021-10-19 | 2023-04-27 | Biosion Inc. | Antibodies binding cldn18.2 and uses thereof |
| CN118139888A (zh) * | 2021-11-05 | 2024-06-04 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体及其用途 |
| CN116162168A (zh) | 2021-11-25 | 2023-05-26 | 信达细胞制药(苏州)有限公司 | 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用 |
| CA3256593A1 (en) * | 2022-06-01 | 2023-12-07 | Integral Molecular, Inc. | Claudine antibodies 18.2, their manufacturing processes and their uses |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2026050213A1 (en) | 2024-08-27 | 2026-03-05 | Usbolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1144629A3 (en) | 1998-09-01 | 2001-11-28 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
| NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
| WO2000015659A2 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
| WO2000020447A2 (en) | 1998-10-06 | 2000-04-13 | Curagen Corporation | Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses |
| CA2383592A1 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| AU7573000A (en) | 1999-09-01 | 2001-03-26 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
| CA2396719A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | 22 human secreted proteins |
| CA2395872A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2001055326A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| EP1254153A2 (en) | 2000-01-31 | 2002-11-06 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2001260847A1 (en) | 2000-05-24 | 2001-12-03 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
| AU8497701A (en) | 2000-08-15 | 2002-02-25 | Immunex Corp | Claudin polypeptides |
| US20030017468A1 (en) | 2000-08-28 | 2003-01-23 | Sei-Yu Chen | Compositions and methods relating to lung specific genes |
| JP2004509617A (ja) | 2000-09-08 | 2004-04-02 | シェーリング コーポレイション | 哺乳動物遺伝子；関連試薬および方法 |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| KR20060134216A (ko) | 2004-04-16 | 2006-12-27 | 에미스페어 테크놀로지스, 인코포레이티드 | 활성제 전달을 위한 8-(2-히드록시페녹시)옥틸디에탄올아민및 그의 염 |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004042822A1 (de) | 2004-08-31 | 2006-03-16 | Technische Universität Dresden | Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen |
| EP1929003A4 (en) | 2005-08-31 | 2009-04-29 | Cell Signaling Technology Inc | REAGENTS FOR DETECTION OF PROTEIN PHOSPORYLATION IN CARCINOMA SIGNALING PATHWAYS |
| EP1930414B1 (en) | 2005-09-08 | 2012-07-18 | Medinet Co., Ltd. | Method for activation treatment of antigen-presenting cell |
| JP5405110B2 (ja) | 2005-09-19 | 2014-02-05 | ベリデックス・エルエルシー | 原発不明がんの原発巣を同定するための方法および材料 |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| LT1976880T (lt) * | 2005-12-21 | 2016-10-10 | Amgen Research (Munich) Gmbh | Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea |
| US20100129929A1 (en) | 2006-07-27 | 2010-05-27 | Roberto Polakewicz | Tyrosine Phosphorylation Sites |
| JP5666136B2 (ja) | 2007-02-01 | 2015-02-12 | ジャンセン ダイアグノスティックス，エルエルシー | 原発不明がんの原発巣を同定するための方法および材料 |
| EP1983002A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2008152822A1 (ja) * | 2007-06-15 | 2008-12-18 | Medinet Co., Ltd. | 医薬 |
| EP2178563A2 (en) | 2007-07-06 | 2010-04-28 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2 |
| EP2036987A1 (en) | 2007-09-17 | 2009-03-18 | Siemens Healthcare Diagnostics GmbH | Molecular markers for tumor cell content in tissue samples |
| AU2009209251B8 (en) | 2008-01-28 | 2015-03-26 | Medimmune Limited | Stabilized Angiopoietin-2 antibodies and uses thereof |
| KR20110018930A (ko) | 2008-06-02 | 2011-02-24 | 엔에스에이비피 파운데이션, 인크. | 암 치료에서 예후적 및 예견적 마커의 확인 및 용도 |
| EP2316026A1 (en) | 2008-07-25 | 2011-05-04 | Merck Patent GmbH | Method of determination of receptor binding saturation effected by monoclonal antibodies |
| WO2010141093A2 (en) * | 2009-06-04 | 2010-12-09 | The University Of Maryland, Baltimore | Co-signaling methods for treating cancers |
| WO2011090005A1 (ja) | 2010-01-19 | 2011-07-28 | 協和発酵キリン株式会社 | 大腸癌の治療用医薬および治療方法 |
| EP2547695B1 (en) | 2010-03-16 | 2018-05-09 | Biontech Protein Therapeutics GmbH | Tumor vaccination involving a humoral immune response against self-protein cldn18.2 |
| CN102168067B (zh) * | 2011-02-11 | 2012-08-29 | 浙江大学 | 一种调节性t细胞的诱导培养方法 |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| JP6241403B2 (ja) | 2014-10-24 | 2017-12-06 | 横浜ゴム株式会社 | リン酸変性ポリマー |
-
2012
- 2012-05-23 WO PCT/EP2012/002211 patent/WO2013174404A1/en not_active Ceased
-
2013
- 2013-05-21 LT LTEP20163993.7T patent/LT3725810T/lt unknown
- 2013-05-21 HR HRP20220897TT patent/HRP20220897T8/hr unknown
- 2013-05-21 SM SM20220325T patent/SMT202200325T1/it unknown
- 2013-05-21 ES ES13729591T patent/ES2784855T3/es active Active
- 2013-05-21 SI SI201332002T patent/SI3725810T1/sl unknown
- 2013-05-21 AU AU2013265637A patent/AU2013265637B8/en active Active
- 2013-05-21 IL IL276434A patent/IL276434B2/en unknown
- 2013-05-21 CN CN201380026898.3A patent/CN104427999B/zh active Active
- 2013-05-21 KR KR1020207034499A patent/KR102514338B1/ko active Active
- 2013-05-21 MX MX2014014215A patent/MX367241B/es active IP Right Grant
- 2013-05-21 CN CN201611203370.0A patent/CN107412773B/zh active Active
- 2013-05-21 RU RU2014152107A patent/RU2662066C2/ru active
- 2013-05-21 CN CN201611203411.6A patent/CN107050460B/zh active Active
- 2013-05-21 JP JP2015513043A patent/JP6203830B2/ja active Active
- 2013-05-21 KR KR1020257016132A patent/KR20250077600A/ko active Pending
- 2013-05-21 UA UAA201413807A patent/UA115985C2/uk unknown
- 2013-05-21 SG SG10201609510UA patent/SG10201609510UA/en unknown
- 2013-05-21 NZ NZ701575A patent/NZ701575A/en unknown
- 2013-05-21 US US14/401,557 patent/US9433675B2/en active Active
- 2013-05-21 SG SG11201406963RA patent/SG11201406963RA/en unknown
- 2013-05-21 RS RS20220682A patent/RS63437B1/sr unknown
- 2013-05-21 PT PT201639937T patent/PT3725810T/pt unknown
- 2013-05-21 IL IL318824A patent/IL318824A/en unknown
- 2013-05-21 KR KR1020147036039A patent/KR102188001B1/ko active Active
- 2013-05-21 ES ES20163993T patent/ES2924023T3/es active Active
- 2013-05-21 PL PL20163993.7T patent/PL3725810T3/pl unknown
- 2013-05-21 HK HK15108681.0A patent/HK1208151A1/xx unknown
- 2013-05-21 BR BR112014028941A patent/BR112014028941B8/pt active IP Right Grant
- 2013-05-21 HU HUE20163993A patent/HUE059241T2/hu unknown
- 2013-05-21 WO PCT/EP2013/001503 patent/WO2013174509A1/en not_active Ceased
- 2013-05-21 KR KR1020237009833A patent/KR102810919B1/ko active Active
- 2013-05-22 AR ARP130101785A patent/AR091131A1/es not_active Application Discontinuation
-
2014
- 2014-11-13 IL IL235672A patent/IL235672B/en active IP Right Grant
- 2014-11-21 MX MX2020011768A patent/MX2020011768A/es unknown
- 2014-11-21 MX MX2020011796A patent/MX2020011796A/es unknown
- 2014-11-21 MX MX2020011795A patent/MX2020011795A/es unknown
- 2014-11-21 MX MX2019009441A patent/MX2019009441A/es unknown
-
2016
- 2016-08-08 US US15/231,185 patent/US10022444B2/en active Active
-
2017
- 2017-08-30 JP JP2017165302A patent/JP6490763B2/ja active Active
-
2018
- 2018-03-15 AU AU2018201856A patent/AU2018201856B2/en active Active
- 2018-05-07 US US15/973,116 patent/US10813996B2/en active Active
-
2019
- 2019-02-27 JP JP2019034057A patent/JP6833885B2/ja active Active
-
2020
- 2020-05-29 AU AU2020203557A patent/AU2020203557A1/en not_active Abandoned
- 2020-08-31 US US17/008,316 patent/US12059464B2/en active Active
-
2021
- 2021-02-03 JP JP2021015688A patent/JP7204791B2/ja active Active
-
2022
- 2022-12-28 JP JP2022212169A patent/JP2023038230A/ja active Pending
-
2023
- 2023-02-08 AU AU2023200682A patent/AU2023200682A1/en active Pending
-
2024
- 2024-06-27 US US18/757,437 patent/US20240335533A1/en active Pending
-
2025
- 2025-02-17 JP JP2025023576A patent/JP2025093926A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018002724A5 (https=) | ||
| RU2014152107A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| RU2014152115A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| ME02932B (me) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera | |
| RU2015139901A (ru) | Комбинированная терапия с использованием антител против клаудина 18.2 для лечения рака | |
| HRP20211346T1 (hr) | Kombinirani pripravci za liječenje raka | |
| JP2020508317A5 (https=) | ||
| JP2018516966A5 (https=) | ||
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| JP2019517549A5 (https=) | ||
| JP2016536314A5 (https=) | ||
| JP2007535895A5 (https=) | ||
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2018508512A5 (https=) | ||
| JP2016530280A5 (https=) | ||
| JP2021511372A5 (https=) | ||
| JP2006265245A5 (https=) | ||
| JP2018518454A5 (https=) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2018508483A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| HRP20221530T1 (hr) | Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke | |
| HRP20221319T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| JP2018531994A5 (https=) |